Alzheimer's disease clinical trials are now underway for seven monoclonal antibodies, one active vaccination, one antisense oligonucleotide (ASO), and four small compounds targeting components of tau protein biology and neurofibrillary tangle production. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.